🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

111 results for “Novo” Clear

  1. A research study looking at how NNC0487-0111 affects food intake, appetite and metabolism after meals in people with obesity

    Novo Nordisk A/S

    Participants with obesity, but otherwise healthy

    phase 1 other active

    1 trial

  2. A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A

    Novo Nordisk A/S

    Haemophilia A with or without inhibitors. Proposed indication under development: prevention of bleeding and long-term prophylaxis in patients with haemophilia A, irrespective of inhibitor status or severity.

    phase 1 other active

    1 trial

  3. A research study looking at how different doses of study medicine (Inno8) works in the body of healthy men.

    Novo Nordisk A/S

    Prophylaxis and on-demand treatment respectively in patients with haemophilia A with or without FVIII inhibitors.

    phase 1 other active

    1 trial

  4. A research study looking into blood levels of the medicine NNC0487 0111 in the body and how well it is tolerated in people with reduced liver function and normal liver function

    Novo Nordisk A/S

    hepatic impairment

    phase 1 other active

    1 trial

  5. A research study looking into how cagrilintide influences food intake and appetite in people with overweight or obesity

    Novo Nordisk A/S

    Obesity

    phase 1 other active

    1 trial

  6. A research study looking into the effect of NNC05190130 on blood levels of a birth control pill and emptying of the stomach in women after menopause

    Novo Nordisk A/S

    Healthy postmenopausal females (Type 2 Diabetes)

    phase 1 other active

    1 trial

  7. A research study of a new medicine (NNC0650-0013) in healthy men

    Novo Nordisk A/S

    Weight management, Diabetes mellitus type 2; healthy subjects

    phase 1 other active

    1 trial

  8. A research study of a new medicine NNC0363-1063 in healthy participants and participants with type 1 diabetes

    Novo Nordisk A/S

    Type 1 diabetes mellitus

    phase 1 other active

    1 trial

  9. A research study of a new medicine NNC0363-1063 in participants with type 1 diabetes

    Novo Nordisk A/S

    Diabetes type 1

    phase 1 other active

    1 trial

  10. A research study of a new medicine, NNC9733-0001, in healthy participants and participants with type 2 diabetes

    Novo Nordisk A/S

    Healthy Participants and Participants with type 2 diabetes

    phase 1 other active

    1 trial

  11. A research study of how safe a new medicine called NNC0519‑0130 is and to test its effect in people living with excess body weight with or without type 2 diabetes

    Novo Nordisk A/S

    Obesity, Type 2 Diabetes with either overweight or obesity

    phase 1 other active

    1 trial

  12. A research study on the effects of NNC0537-1482 in healthy individuals when injected under the skin.

    Novo Nordisk A/S

    Heart Failure

    phase 1 other active

    1 trial

  13. A research study to compare blood levels of cagrilintide after multiple doses of different versions of cagrilintide in adults with overweight or obesity

    Novo Nordisk A/S

    obesity

    phase 1 other active

    1 trial

  14. A research study to evaluate the effects of single doses of NNC0614-0001 in healthy adult volunteers, and participants with hereditary haemochromatosis type 1.

    Novo Nordisk A/S

    Hereditary haemochromatosis (HH) type 1

    phase 1 other active

    1 trial

  15. A research study to evaluate the safety of NNC1679-0001 when given to healthy participants and participants with T2DM

    Novo Nordisk A/S

    Healthy participants and participants with type 2 diabetes

    phase 1 other active

    1 trial

  16. A research study to look at how CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight

    Novo Nordisk A/S

    Obesity

    phase 1 other active

    1 trial

  17. A research study to look at the distribution and effects of coramitug on amyloid deposits in heart tissue using PET/CT imaging in people with ATTR amyloidosis

    Novo Nordisk A/S

    transthyretin amyloid amyloidosis cardiomyopathy (ATTR-CM)

    phase 1 other active

    1 trial

  18. A research study to see how NNC0487-0111 affects the body’s energy use after a weight loss in adults living with obesity, compared to a low-calorie diet or placebo

    Novo Nordisk A/S

    Obesity

    phase 1 other active

    1 trial

  19. A study investigating the safety, absorption, and elimination of NNC0705-0001, a new compound that could potentially be used in the treatment of cardiometabolic diseases caused by inflammation.

    Novo Nordisk A/S

    Cardiometabolic diseases with an inflammatory component

    phase 1 other active

    1 trial

  20. A study of how CagriSema works on appetite in people with excess body weight

    Novo Nordisk A/S

    Obesity

    phase 1 other active

    1 trial

  21. A study to see the effect of NNC0194-0499 alone or in combination with semaglutide on blood sugar control in people living with type 1 diabetes.

    Novo Nordisk A/S

    Diabetes mellitus type 1

    phase 1 other active

    1 trial

  22. A study to test how a new long-acting insulin works in the body of patients with type 2 diabetes during exercise and prolonged fasting.

    Novo Nordisk A/S

    Type 2 diabetes

    phase 1 other active

    1 trial

  23. A study to test how insulin NNC0471-0119 H works in the body in participants with type 1 diabetes when given by an insulin pump.

    Novo Nordisk A/S

    Diabetes mellitus type 1

    phase 1 other active

    1 trial

  24. A study to test how insulin NNC0471-0119 works in the body in participants with type 2 diabetes when given by an insulin pump.

    Novo Nordisk A/S

    Diabetes mellitus type 2

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources